What is this study trying to find out about acute respiratory failure?

This study aims to develop an AI-based model to group patients with acute respiratory failure by their clinical features and outcomes. Researchers want to better understand patient types and compare those needing advanced oxygen support to those who do not. The study is sponsored by Samsung Medical Center and seeks to improve personalized care approaches.

Who may be eligible for this acute respiratory failure clinical trial?

Adults aged 18 or older admitted to the internal medicine ICU are eligible. Participants either require advanced oxygen support like high flow nasal cannula or mechanical ventilation, or do not need such treatments for the control group. There is no gender restriction. Please review eligibility criteria for more details.

Is there any cost to participate in this acute respiratory failure clinical trial?

Study-related care, including all research procedures, is provided at no cost. However, personal expenses such as travel costs may vary and are not guaranteed to be reimbursed. Participants should plan accordingly for any additional expenses.

Actively Recruiting

Age: 18Years +

All Genders

ID06479421

A Clinical Study for Developing AI-based Clustering Model for Personalized Medicine in Acute Respiratory Failure Single Center, Prospective Cohort Study

Led by Samsung Medical Center · Updated on 2026-04-28

250

Participants Needed

Research Sites

52 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are conducting a clinical study to develop an artificial intelligence AI-based clustering model to personalize medicine for patients with acute respiratory failure who are admitted to the intensive care unit ICU. The study aims to confirm patient phenotypes and compare clinical characteristics and prognosis between patients requiring advanced oxygen support and a control group without acute respiratory failure. Participants are divided into two groups those with acute respiratory failure requiring treatment with high flow nasal cannula HFNC, non-invasive ventilation NIV, or mechanical ventilation MV, and a control group who do not need these treatments. Both groups are admitted to the internal medicine ICU at Samsung Seoul Hospital and undergo the same research procedures. During the study, participants clinical information is collected prospectively for analysis. Researchers will assess hospital mortality up to one year from admission, ICU mortality up to six months, and length of stay in both hospital and ICU. The study involves monitoring patients from admission until discharge or death, with follow-up periods varying up to one year. This observational study is sponsored by Samsung Medical Center.

CONDITIONS

Brief Title

A Clinical Study for Developing Artificial Intelligence(AI)-Based Clustering Model for Personalized Medicine in Acute Respiratory Failure

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Age 18 or older
For acute respiratory failure group: patients admitted to the internal medicine ICU requiring treatment with high flow nasal cannula, non-invasive ventilation (BIPAP or CPAP), or mechanical ventilation due to acute respiratory failure
For control group: patients admitted to the internal medicine ICU who do not require treatment with high flow nasal cannula, non-invasive ventilation, or mechanical ventilation and consent to participate

You will not qualify if you...

Patients who have been receiving oxygen treatment (HFNC, NIV, or MV) for more than 48 hours
Patients transferred from another hospital
Patients with limitations in treatment

Research Team

Ryoung Eun Ko, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here